Dr. Anas Zaher presenting data on endoscopic stricturotomy for IBD-related strictures and endoscopic balloon dilation vs. self-dilation in patients with IPAA #ACG2026
Patients with IBD and comorbid obstructive sleep apnea (OSA) experience greater corticosteroid exposure and increased healthcare utilization, including ED visits and hospitalizations, as presented by Dr. Shay Bidani at #ACG2026!
Dr. Burstiner presenting his #ACG2026 poster entitled, "Young Adult Males with Crohn's Disease Have a 17.3% Risk of Major IBD Surgery." Pictured here with one his mentors, Dr. Royer.
College students with IBD reported their experience with and impact of marijuana use in a mixed methods study, presented by Dr. Arvin Daneshmand at #ACG2026 !
Dr. Tyler Rice presented at #ACG2026 and received an Outstanding Poster Presenter Award! Our study found that patients with both IBD and EoE had greater outpatient GI utilization, corticosteroid exposure, and advanced therapy use compared with patients with IBD alone.
Evan Hamill presented our case report on severe gastric injury from accidental 35% hydrogen peroxide ingestion at #ACG2026 in Nashville!
New research from the University of Florida examines cardiovascular risk associated with advanced therapies in #IBD.
This systematic review and meta-analysis of 43 studies found no clear increase or decrease in major cardiovascular event risk with advanced therapies.
New research from the University of Florida finds that age, rather than social vulnerability, is associated with disparities in IBD prescription patterns.
The nationwide Epic Cosmos study included more than 60,000 patients with IBD.
sciencedirect.com/science/ar…
Hot off the press!
Our latest study examines patterns of marijuana use, symptom response, and perceptions among individuals with IBD, with many reporting perceived improvements in symptom control and quality of life. #IBDresearch
doi.org/10.1159/000553354
At #DDW2026, Chloe Jian examined biologic treatment patterns and adherence measurement in patients with IBD across pharmacy dispensing and HCPCS-coded medical claims, showing that biologic adherence estimates are highly sensitive to exposure definitions and claims capture routes.
Using U.S. claims data, Chloe Jian found that GLP-1 RA use was associated with improved IBD-related outcomes compared with DPP-4 inhibitors among patients with type 2 diabetes and IBD, suggesting potential anti-inflammatory and disease-modifying effects of GLP-1 RAs #DDW2026
At #DDW2026, Anshul Mahajan presented research on healthcare utilization in IBD patients with comorbid intellectual disability. Patients with ID-IBD had significantly higher clinic visits, ED visits, hospital days, and colonoscopies despite similar biologic use and surgical rates
At #DDW2026, Anshul Mahajan presented research on the prevalence of early-onset cataracts in young patients with IBD under age 50. Cataracts were rare overall, but cumulative corticosteroid exposure was identified as a key modifiable risk factor associated with increased risk.
At #DDW2026, Tomas Potlach reported a post-hoc analysis of the UNITI clinical trials for ustekinumab, highlighting differences in clinical response and remission during induction therapy between young adults aged 18-25 and older adults aged 26+.
At #DDW2026, Shay Bidani shared results from a national survey of college students with IBD. Over half reported academic disruptions, with key risk factors including prior surgery, off-campus housing, and minority status, highlighting opportunities for earlier, targeted support.
At #DDW2026, Nofel Iftikhar presented research on advanced therapies in IBD and their impact on neurodegenerative outcomes. Patients on advanced therapies demonstrated lower odds of neurodegenerative disorders, suggesting potential benefits that extend beyond IBD management.
At #DDW2026, Dr. Chris Miquel-Chambers looked at factors related to ostomy reversal in IBD patients using a large population dataset and classified reversal rates by IBD subtype and behavior. Congratulations on being selected as a poster of distinction!
New from Qi Jian and the UF IBD team in JAMA Network Open:
Among 16,387 older adults with IBD, immunomodulators and biologics were not associated with increased MACE risk compared to 5-ASA over up to 3 years of follow-up. #IBD #HealthOutcomes
jamanetwork.com/journals/jam…
Aniruddh Setya, MD will be leading our next UF IBD webinar! See flyer for more info.
When: May 21st 6-7pm EST
Where: Zoom
Register here: ufl.zoom.us/webinar/register…

















